Download PDF
CC BY-NC-ND 4.0 · Thromb Haemost 2023; 123(04): 402-414
DOI: 10.1055/a-1981-1763
Coagulation and Fibrinolysis

Assessment of DOAC in GEriatrics (Adage Study): Rivaroxaban/Apixaban Concentrations and Thrombin Generation Profiles in NVAF Very Elderly Patients

Geoffrey Foulon-Pinto   *
1   Université Paris Cité, INSERM UMR-S-1140, Innovations Thérapeutiques en Hémostase, Paris, France
2   Service d'Hématologie Biologique, AP-HP. Université Paris Cité, Hôpital Lariboisière, Paris, France
,
Carmelo Lafuente-Lafuente   *
3   Service de gériatrie à orientation cardiologique et neurologique, AP-HP, Sorbonne Université, Hôpitaux universitaires Pitié-Salpêtrière-Charles Foix, Ivry-sur-Seine, France
4   CEpiA Team (Clinical Epidemiology and Ageing), Université Paris Est Créteil, INSERM, IMRB, Créteil, France
,
Georges Jourdi
1   Université Paris Cité, INSERM UMR-S-1140, Innovations Thérapeutiques en Hémostase, Paris, France
5   Research Center, Institut de Cardiologie de Montréal - Université de Montréal, Montréal, QC, Canada
,
Julien Le Guen
6   Service de Gériatrie, AP-HP. Université Paris Cité, Hôpital Européen Georges Pompidou, Paris, France
,
Fatoumata Tall
7   Service de Gériatrie, AP-HP. Université Paris Cité, Hôpital Rothschild, Paris, France
,
Etienne Puymirat
8   Service de Cardiologie, AP-HP. Université de Paris Cité, Hôpital Européen Georges Pompidou, Paris, France
,
Maxime Delrue
2   Service d'Hématologie Biologique, AP-HP. Université Paris Cité, Hôpital Lariboisière, Paris, France
,
Léa Rivière
9   Service de gériatrie aiguë polyvalente, Hôpital Charles-Foix, AP-HP Sorbonne Université, Ivry-sur-Seine, France, UFR Médecine Sorbonne Université, Paris, France
,
Flora Ketz
9   Service de gériatrie aiguë polyvalente, Hôpital Charles-Foix, AP-HP Sorbonne Université, Ivry-sur-Seine, France, UFR Médecine Sorbonne Université, Paris, France
,
Isabelle Gouin-Thibault
10   INSERM, CIC 1414 (Centre d'Investigation Clinique de Rennes), Université de Rennes, CHU de Rennes, Rennes, France
11   Service d'Hématologie Biologique, CHU de Rennes, Rennes, France
,
François Mullier 
12   Department of Laboratory Medicine, Namur Thrombosis and Hemostasis Center (NTHC), Université Catholique de Louvain, Yvoir, Belgium
13   Hematology-Hemostasis Laboratory, CHU UCL Namur, Yvoir, Belgium
,
Pascale Gaussem
1   Université Paris Cité, INSERM UMR-S-1140, Innovations Thérapeutiques en Hémostase, Paris, France
14   Service d'Hématologie Biologique, AP-HP. Université Paris Cité, Hôpital Européen Georges Pompidou, Paris, France
,
Eric Pautas
1   Université Paris Cité, INSERM UMR-S-1140, Innovations Thérapeutiques en Hémostase, Paris, France
9   Service de gériatrie aiguë polyvalente, Hôpital Charles-Foix, AP-HP Sorbonne Université, Ivry-sur-Seine, France, UFR Médecine Sorbonne Université, Paris, France
,
Thomas Lecompte
11   Service d'Hématologie Biologique, CHU de Rennes, Rennes, France
15   Université de Lorraine, Faculté de médecine de Nancy, Nancy, France
,
Emmanuel Curis   *
16   Université de Paris Cité, UR 7537 BioSTM (Biostatistics), Faculté de Pharmacie, Paris, France
,
Virginie Siguret    *
1   Université Paris Cité, INSERM UMR-S-1140, Innovations Thérapeutiques en Hémostase, Paris, France
2   Service d'Hématologie Biologique, AP-HP. Université Paris Cité, Hôpital Lariboisière, Paris, France
› Author Affiliations Funding Reagents were purchased thanks to a CONNY-MAEVA Charitable Foundation grant and the Société Française de Cardiologie. The funding sources had no role in the design and conduct of the study, collection, management, analysis, and interpretation of the data.
› Further Information
   Permissions and Reprints


Abstract

Background Although a growing number of very elderly patients with atrial fibrillation (AF), multiple conditions, and polypharmacy receive direct oral anticoagulants (DOACs), few studies specifically investigated both apixaban/rivaroxaban pharmacokinetics and pharmacodynamics in such patients.

Aims To investigate: (1) DOAC concentration–time profiles; (2) thrombin generation (TG); and (3) clinical outcomes 6 months after inclusion in very elderly AF in-patients receiving rivaroxaban or apixaban.

Methods Adage-NCT02464488 was an academic prospective exploratory multicenter study, enrolling AF in-patients aged ≥80 years, receiving DOAC for at least 4 days. Each patient had one to five blood samples at different time points over 20 days. DOAC concentrations were determined using chromogenic assays. TG was investigated using ST-Genesia (STG-ThromboScreen, STG-DrugScreen).

Results We included 215 patients (women 71.1%, mean age: 87 ± 4 years), 104 rivaroxaban and 111 apixaban, and 79.5% receiving reduced-dose regimen. We observed important inter-individual variabilities (coefficient of variation) whatever the regimen, at C max [49–46%] and C min [75–61%] in 15 mg rivaroxaban and 2.5 mg apixaban patients, respectively. The dose regimen was associated with C max and C min plasma concentrations in apixaban (p = 0.0058 and p = 0.0222, respectively), but not in rivaroxaban samples (multivariate analysis). Moreover, substantial variability of thrombin peak height (STG-ThromboScreen) was noticed at a given plasma concentration for both xabans, suggesting an impact of the underlying coagulation status on TG in elderly in-patients. After 6-month follow-up, major bleeding/thromboembolic event/death rates were 6.7%/1.0%/17.3% in rivaroxaban and 5.4%/3.6%/18.9% in apixaban patients, respectively.

Conclusion Our study provides original data in very elderly patients receiving DOAC in a real-life setting, showing great inter-individual variability in plasma concentrations and TG parameters. Further research is needed to understand the potential clinical impact of these findings.

Keywords

apixaban - atrial fibrillation - elderly - rivaroxaban - thrombin generation

Authors Contribution

G.F.-P., V.S., G.J., and E.C. wrote the manuscript; C.L-L, V.S., E.P., and I.G.-T designed the research; C.L-L, J.L, E.P., and M.D. were clinical investigators; G.F.-P., V.S., G.J., F.T., F.K., and L.R. performed the research; G.F.-P., V.S., G.J., T.L., and E.C. analyzed the data; all authors reviewed the manuscript.


* These authors share equal authorship.


Supplementary Material



Publication History

Received: 09 August 2022

Accepted: 18 October 2022

Accepted Manuscript online:
17 November 2022

Article published online:
09 January 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Chugh SS, Havmoeller R, Narayanan K. et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014; 129 (08) 837-847
    CrossrefPubMedGoogle Scholar
  • 2 Hindricks G, Potpara T, Dagres N. et al; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42 (05) 373-498
    Google Scholar
  • 3 January CT, Wann LS, Calkins H. et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation 2019; 140 (02) e125-e151
    CrossrefPubMedGoogle Scholar
  • 4 Hanna MS, Mohan P, Knabb R, Gupta E, Frost C, Lawrence JH. Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation. Ann N Y Acad Sci 2014; 1329: 93-106
    CrossrefPubMedGoogle Scholar
  • 5 Kubitza D, Becka M, Roth A, Mueck W. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008; 24 (10) 2757-2765
    CrossrefPubMedGoogle Scholar
  • 6 Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78 (04) 412-421
    CrossrefPubMedGoogle Scholar
  • 7 Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 2014; 53 (01) 1-16
    CrossrefPubMedGoogle Scholar
  • 8 Patel MR, Mahaffey KW, Garg J. et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
    Google Scholar
  • 9 Granger CB, Alexander JH, McMurray JJV. et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
    Google Scholar
  • 10 Bayer AG. Xarelto 20 mg film-coated tablets SmPC. Published online January 17, 2020. Accessed October 8, 2020 at: https://www.ema.europa.eu/en/documents/product-information/xarelto-epar-product-information_en.pdf
    PubMedGoogle Scholar
  • 11 Bristol-Myers Squibb/Pfizer EEIG. Eliquis 5 mg film-coated tablets SmPC. Published online September 16, 2020. Accessed October 8, 2020 at: https://www.ema.europa.eu/en/documents/product-information/eliquis-epar-product-information_en.pdf
    PubMedGoogle Scholar
  • 12 Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation 2015; 132 (03) 194-204
    CrossrefPubMedGoogle Scholar
  • 13 Mitchell A, Watson MC, Welsh T, McGrogan A. Effectiveness and safety of direct oral anticoagulants versus vitamin k antagonists for people aged 75 years and over with atrial fibrillation: a systematic review and meta-analyses of observational studies. J Clin Med 2019; 8 (04) E554
    CrossrefPubMedGoogle Scholar
  • 14 Alexander JH, Andersson U, Lopes RD. et al; Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) Investigators. Apixaban 5 mg twice daily and clinical outcomes in patients with atrial fibrillation and advanced age, low body weight, or high creatinine: a secondary analysis of a randomized clinical trial. JAMA Cardiol 2016; 1 (06) 673-681
    CrossrefPubMedGoogle Scholar
  • 15 Deitelzweig S, Keshishian A, Li X. et al. Comparisons between oral anticoagulants among older nonvalvular atrial fibrillation patients. J Am Geriatr Soc 2019; 67 (08) 1662-1671
    CrossrefPubMedGoogle Scholar
  • 16 Kubitza D, Becka M, Roth A, Mueck W. The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban–an oral, direct Factor Xa inhibitor. J Clin Pharmacol 2013; 53 (03) 249-255
    CrossrefPubMedGoogle Scholar
  • 17 Mueck W, Schwers S, Stampfuss J. Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J 2013; 11 (01) 10
    CrossrefPubMedGoogle Scholar
  • 18 Frost C, Wang J, Nepal S. et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 2013; 75 (02) 476-487
    CrossrefPubMedGoogle Scholar
  • 19 Frost CE, Song Y, Shenker A. et al. Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban. Clin Pharmacokinet 2015; 54 (06) 651-662
    CrossrefPubMedGoogle Scholar
  • 20 Gong IY, Kim RB. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol 2013; 29 (7, Suppl): S24-S33
    CrossrefPubMedGoogle Scholar
  • 21 Girgis IG, Patel MR, Peters GR. et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF. J Clin Pharmacol 2014; 54 (08) 917-927
    CrossrefPubMedGoogle Scholar
  • 22 Al-Aieshy F, Malmström RE, Antovic J. et al. Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation. Eur J Clin Pharmacol 2016; 72 (06) 671-679
    CrossrefPubMedGoogle Scholar
  • 23 Testa S, Tripodi A, Legnani C. et al; START-Laboratory Register. Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: results observed in four anticoagulation clinics. Thromb Res 2016; 137: 178-183
    CrossrefPubMedGoogle Scholar
  • 24 Cirincione B, Kowalski K, Nielsen J. et al. Population pharmacokinetics of apixaban in subjects with nonvalvular atrial fibrillation. CPT Pharmacometrics Syst Pharmacol 2018; 7 (11) 728-738
    CrossrefPubMedGoogle Scholar
  • 25 Testa S, Paoletti O, Legnani C. et al. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost 2018; 16 (05) 842-848
    CrossrefPubMedGoogle Scholar
  • 26 Miklič M, Mavri A, Vene N. et al. Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation. Eur J Clin Pharmacol 2019; 75 (08) 1069-1075
    CrossrefPubMedGoogle Scholar
  • 27 Bendayan M, Mardigyan V, Williamson D. et al. Muscle mass and direct oral anticoagulant activity in older adults with atrial fibrillation. J Am Geriatr Soc 2021; 69 (04) 1012-1018
    CrossrefPubMedGoogle Scholar
  • 28 Nissan R, Spectre G, Hershkovitz A. et al. Apixaban levels in octogenarian patients with non-valvular atrial fibrillation. Drugs Aging 2019; 36 (02) 165-177
    CrossrefPubMedGoogle Scholar
  • 29 Sukumar S, Gulilat M, Linton B. et al. Apixaban concentrations with lower than recommended dosing in older adults with atrial fibrillation. J Am Geriatr Soc 2019; 67 (09) 1902-1906
    CrossrefPubMedGoogle Scholar
  • 30 Tripodi A. Thrombin generation assay and its application in the clinical laboratory. Clin Chem 2016; 62 (05) 699-707
    CrossrefPubMedGoogle Scholar
  • 31 Pfrepper C, Metze M, Siegemund A, Klöter T, Siegemund T, Petros S. Direct oral anticoagulant plasma levels and thrombin generation on ST Genesia system. Res Pract Thromb Haemost 2020; 4 (04) 619-627
    CrossrefPubMedGoogle Scholar
  • 32 Binder NB, Depasse F, Mueller J. et al. Clinical use of thrombin generation assays. J Thromb Haemost 2021; 19 (12) 2918-2929
    CrossrefPubMedGoogle Scholar
  • 33 Meihandoest T, Studt JD, Mendez A. et al. Automated thrombin generation assay for rivaroxaban, apixaban, and edoxaban measurements. Front Cardiovasc Med 2021; 8: 717939
    CrossrefPubMedGoogle Scholar
  • 34 Hemker HC, Al Dieri R, De Smedt E, Béguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 2006; 96 (05) 553-561
    PubMedGoogle Scholar
  • 35 Foulon-Pinto G, Jourdi G, Perrin J. et al. Study of thrombin generation with St Genesia to evaluate xaban pharmacodynamics: analytical performances over 18 months. Int J Lab Hematol 2021; 43 (04) 821-830
    CrossrefPubMedGoogle Scholar
  • 36 Douxfils J, Adcock DM, Bates SM. et al. 2021 Update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost 2021; 121 (08) 1008-1020
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Miller MD, Paradis CF, Houck PR. et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 1992; 41 (03) 237-248
    CrossrefPubMedGoogle Scholar
  • 38 Service de pharmacologie et toxicologie cliniques - Hôpitaux universitaires de Genève. Interactions médicamenteuses, cytochromes P450 et P-glycoprotéine (Pgp). Published 2020. Accessed June 20, 2022 at: https://www.hug.ch/sites/interhug/files/structures/pharmacologie_et_toxicologie_cliniques/images/carte_des_cytochromes_2020.pdf
    PubMed
  • 39 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
    CrossrefPubMedGoogle Scholar
  • 40 Pinheiro J, Bates D, DebRoy S, Sarkar D. Nlme: linear and nonlinear mixed effects models. 2021. Accessed December 13, 2022 at: https://CRAN.R-project.org/package=nlme
    PubMed
  • 41 R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. 2020. Accessed December 13, 2022 at: https://www.R-project.org/
    PubMed
  • 42 Hirsh Raccah B, Rottenstreich A, Zacks N. et al. Appropriateness of direct oral anticoagulant dosing and its relation to drug levels in atrial fibrillation patients. J Thromb Thrombolysis 2019; 47 (04) 550-557
    CrossrefPubMedGoogle Scholar
  • 43 Comans AL, Sennesael AL, Bihin B, Regnier M, Mullier F, de Saint-Hubert M. Inappropriate low dosing of direct oral anticoagulants in older patients with non-valvular atrial fibrillation: impact on plasma drug levels. Thromb Res 2021; 201: 139-142
    CrossrefPubMedGoogle Scholar
  • 44 Steinberg BA, Shrader P, Thomas L. et al; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). Am Heart J 2017; 189: 40-47
    CrossrefPubMedGoogle Scholar
  • 45 Yao X, Tangri N, Gersh BJ. et al. Renal outcomes in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 2017; 70 (21) 2621-2632
    CrossrefPubMedGoogle Scholar
  • 46 Camm AJ, Cools F, Virdone S. et al; GARFIELD-AF Investigators. Mortality in patients with atrial fibrillation receiving nonrecommended doses of direct oral anticoagulants. J Am Coll Cardiol 2020; 76 (12) 1425-1436
    CrossrefPubMedGoogle Scholar
  • 47 Sugrue A, Sanborn D, Amin M. et al. Inappropriate dosing of direct oral anticoagulants in patients with atrial fibrillation. Am J Cardiol 2021; 144: 52-59
    CrossrefPubMedGoogle Scholar
  • 48 Roşian AN, Roşian ŞH, Kiss B. et al. Interindividual variability of apixaban plasma concentrations: influence of clinical and genetic factors in a real-life cohort of atrial fibrillation patients. Genes (Basel) 2020; 11 (04) E438
    CrossrefPubMedGoogle Scholar
  • 49 Raymond J, Imbert L, Cousin T. et al. Pharmacogenetics of direct oral anticoagulants: a systematic review. J Pers Med 2021; 11 (01) 37
    CrossrefPubMedGoogle Scholar
  • 50 Ueshima S, Hira D, Fujii R. et al. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation. Pharmacogenet Genomics 2017; 27 (09) 329-336
    CrossrefPubMedGoogle Scholar
  • 51 Gouin-Thibault I, Delavenne X, Blanchard A. et al. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. J Thromb Haemost 2017; 15 (02) 273-283
    CrossrefPubMedGoogle Scholar
  • 52 Lähteenmäki J, Vuorinen AL, Pajula J. et al. Pharmacogenetics of bleeding and thromboembolic events in direct oral anticoagulant users. Clin Pharmacol Ther 2021; 110 (03) 768-776
    CrossrefPubMedGoogle Scholar
  • 53 Gulilat M, Keller D, Linton B. et al. Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care. J Thromb Thrombolysis 2020; 49 (02) 294-303
    CrossrefPubMedGoogle Scholar
  • 54 Kreutz R, Persson PB, Kubitza D. et al. Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study. J Thromb Haemost 2017; 15 (10) 2017-2028
    CrossrefPubMedGoogle Scholar
  • 55 Artang R, Anderson M, Riley P, Nielsen JD. Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay. Res Pract Thromb Haemost 2017; 1 (02) 194-201
    CrossrefPubMedGoogle Scholar
  • 56 Bertaggia-Calderara D, Kröll D, Gerschheimer C. et al. Effect of rivaroxaban on thrombin generation in vivo. A study in obese patients. Int J Lab Hematol 2018; 40 (01) e11-e14
    CrossrefPubMedGoogle Scholar
  • 57 Siguret V, Abdoul J, Delavenne X. et al. Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: modeling and assessing interindividual variability. J Thromb Haemost 2019; 17 (10) 1670-1682
    CrossrefPubMedGoogle Scholar
  • 58 Sepúlveda C, Palomo I, Fuentes E. Primary and secondary haemostasis changes related to aging. Mech Ageing Dev 2015; 150: 46-54
    CrossrefPubMedGoogle Scholar
  • 59 Hanon O, Vidal JS, Pisica-Donose G. et al; SAFIR study group. Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation. Heart 2021; 107 (17) 1376-1382
    CrossrefPubMedGoogle Scholar